register

News & Trends - Pharmaceuticals

First skin lymphoma therapy PBS listed through Arrotex and Juniper Biologics partnership

Health Industry Hub | November 1, 2024 |

Pharma News: The first ever treatment for Australians living with early-stage mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) is now listed on the Pharmaceutical Benefits Scheme (PBS). MF accounts for nearly 50% of all primary cutaneous lymphomas, a type of non-Hodgkin’s lymphoma.

Topical Ledaga (chlormethine gel) has become available locally through a partnership between Arrotex Pharmaceuticals, the largest Australian-owned pharmaceutical company, and Singapore-based Juniper Biologics. In 2022, Juniper Biologics secured an exclusive distribution license and supply agreement to register, distribute, promote, market, and sell Ledaga across Australia, Asia, and the Middle East.

Professor Miles Prince AM, a leading haematologist and Director of Molecular Oncology and Cancer Immunology at Epworth Healthcare, has been a strong advocate for the approval of Ledaga.

“Sadly, this condition is incurable, and patients suffer from pain, constant itch, and often the cosmetic impact of the disease involving their skin,” he remarked. “Something that can be easily applied and one that is so effective is life-changing for my patients.”

While the cause of MF remains unknown, it is characterised by an indolent clinical course, gradually progressing from patches to thicker plaques and, eventually, to tumours over years or even decades.

Caroline Guerbet, Marketing Director at Juniper Biologics, emphasised the significance of the partnership with Arrotex.

“This finally offers hope for those Australians who have this lifelong, painful disease. We believe in developing game-changing medicines, such as Ledaga, to help treat some of the most complex and pressing illnesses of our time,” Guerbet stated.

The European Organisation for Research and Treatment of Cancer (EORTC) recommends Ledaga as a first-line treatment for early-stage disease. The pivotal 201 study, the largest randomised controlled trial ever conducted for early-stage MF-CTCL, involved 260 patients.

Results revealed that 77% of those treated for at least six months with Ledaga achieved a clinical response according to the Composite Assessment of Index Lesion Severity (CAILS) score, compared to 59% in the control group. Furthermore, a complete response was achieved in 19% of patients receiving Ledaga versus 15% in the control group, with reductions in mean CAILS scores observed as early as four weeks into the study.

Ledaga is also the inaugural therapy launched under the new ‘Arrotex Innovation Hub,’ aimed at delivering hard-to-access, cutting-edge treatments to Australians in need.

Monique Jonson, the new Head of Innovation at Arrotex, described the partnership with Juniper Biologics as a testament to Arrotex’s commitment to addressing the unmet clinical needs of vulnerable patients.

Dr Jillian Wells from the Cutaneous Lymphoma Clinic at Westmead Hospital echoed this sentiment, stating, “This is great news for the 2,000 or so Australians living with MF-CTCL. The dermatologists and haematologists who treat patients with this terrible disease can now finally offer an effective and convenient treatment option.”

Sharon Winton, CEO of the patient advocacy group Lymphoma Australia, expressed optimism about the treatment’s potential impact.

“Ledaga will give MF patients the hope of a symptom-free, relatively normal life,” she said.

As part of its Innovation Hub, Arrotex is actively exploring further opportunities, both independently and in collaboration with global partners, to introduce vital therapies currently unavailable in Australia.

Hayley Tamborini, Chief Commercial Officer of Arrotex, emphasised the company’s mission, saying “Taking on complex challenges is in Arrotex’s DNA. We are an Australian company focused on ensuring Australians have timely, sustainable, and affordable access to world-class treatments.”

In reimagining healthcare, Health Industry HubTM is the ONLY one-stop-hub uniting the diversity of Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change. The exclusive leadership and influencer podcasts and vodcasts offer unparalleled insights and add immense value to our breaking news coverage.

The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.


ESG

Edwards Lifesciences VP challenges us to 'dream bigger' for underserved communities

Edwards Lifesciences VP challenges us to ‘dream bigger’ for underserved communities

Health Industry Hub | November 11, 2024 |

Social Impact: Edwards Lifesciences ANZ held its annual Foundation Grants Day, an event that brought to life the company’s commitment […]

More


News & Trends - MedTech & Diagnostics

Government faces scrutiny for inaction in private hospital sector despite Health Check warnings

Government faces scrutiny for inaction in private hospital sector despite Health Check warnings

Health Industry Hub | November 11, 2024 |

Shadow Health Minister Senator Anne Ruston questioned the Department of Health’s commitment to addressing critical issues in the private hospital […]

More


News & Trends - MedTech & Diagnostics

Australia lags behind in funding pharmacogenomic testing: Pathologists urge action

Australia lags behind in funding pharmacogenomic testing: Pathologists urge action

Health Industry Hub | November 11, 2024 |

Diagnostics & MedTech News: The call for urgent action to improve access to pharmacogenomic testing across Australia comes as demand […]

More


News & Trends - Pharmaceuticals

Australia’s first Cholesterol Awareness Week launched to tackle nation’s 'silent disease'

Australia’s first Cholesterol Awareness Week launched to tackle nation’s ‘silent disease’

Health Industry Hub | November 11, 2024 |

Pharma News: Leading heart charities have come together to launch the nation’s first Cholesterol Awareness Week (11-17 November), aiming to […]

More


This content is copyright protected. Please subscribe to gain access.